Ayurveda and yoga in cardiovascular diseases
ABSTRACT Ayurveda is derived from 2 Sanskrit words, namely, "Ayus" and "Veda," meaning life and knowledge, respectively. It literally means science of life. Ayurveda, of which yoga is an integral part, is widely practiced in India and is gaining acceptance in many countries around the world. It is a comprehensive and a holistic system, the focus of which is on the body, mind, and consciousness. The Ayurvedic treatment consists of the use herbal preparations, diet, yoga, meditation, and other practices. Based on the review of available studies, the evidence is not convincing that any Ayurvedic herbal treatment is effective in the treatment of heart disease or hypertension. However, the use of certain spices and herbs such as garlic and turmeric in an overall healthy diet is appropriate. Many herbs used by Ayurvedic practitioners show promise and could be appropriate for larger randomized trials. Yoga, an integral part of Ayurveda, has been shown to be useful to patients with heart disease and hypertension. Yoga reduces anxiety, promotes well-being, and improves quality of life. Its safety profile is excellent. Its use as a complementary therapeutic regimen under medical supervision is appropriate and could be worth considering.
- SourceAvailable from: Vadde Ramakrishna
[Show abstract] [Hide abstract]
- "Its safety profile is excellent. Its use as a complementary therapeutic regimen under medical supervision is appropriate and could be worth considering (Mamtani, 2005). The literature suggests that some CAM approaches may be beneficial as adjuncts to conventional management of cardiovascular disease, but no evidence exists to support their role as primary treatment (Koscielny et al., 1999; Miller et al., 2004). "
ABSTRACT: Plants have served as traditional herbal medicines for long time, and natural products make excellent leads for new drug development. These products are mostly secondary metabolites, and have become medicines, dietary supplements, and other useful commercial products. These active lead compounds can also be further modified to enhance the biological profiles and developed as clinical trial candidates. The efficacy and safety of any pharmaceutical product is determined by the components (desired and undesired) which it contains. Mixture of compounds produced by plants may provide important combination therapies that simultaneously affect multiple pharmacological targets and provide clinical efficacy beyond the reach of single compound-based drugs. Developing innovative scientific methods for discovery, validation, characterization and standardization of these components is essential to their acceptance into mainstream medicine. In this review, we focus on latest developments in plant products research at global level with special reference to safety, efficacy and preclinical evaluation for various diseases that are reported in different laboratories.01/2009: chapter Comp. Bio. Nat. Pro. Vol III;
- [Show abstract] [Hide abstract]
ABSTRACT: Yoga has become increasingly popular in Western cultures as a means of exercise and fitness training; however, it is still depicted as trendy as evidenced by an April 2001 Time magazine cover story on "The Power of Yoga." There is a need to have yoga better recognized by the health care community as a complement to conventional medical care. Over the last 10 years, a growing number of research studies have shown that the practice of Hatha Yoga can improve strength and flexibility, and may help control such physiological variables as blood pressure, respiration and heart rate, and metabolic rate to improve overall exercise capacity. This review presents a summary of medically substantiated information about the health benefits of yoga for healthy people and for people compromised by musculoskeletal and cardiopulmonary disease.The Journal of Alternative and Complementary Medicine 01/2003; 8(6):797-812. DOI:10.1089/10755530260511810 · 1.52 Impact Factor
- Current Problems in Cardiology 09/2005; 30(8):383-459. DOI:10.1016/j.cpcardiol.2005.01.003 · 2.17 Impact Factor